An official website of the United States government Here's how you know

The .gov means it's official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you're on a federal government site.

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Drugs@FDA: FDA-Approved Drugs

Home | Previous Page

New Drug Application (NDA): 208603
Company: ZYLA

Medication Guide

FDA has determined that this product has abuse-deterrent properties

REMS

Products on NDA 208603

Drug Name	Active Ingredients	Strength	Dosage Form/Route	Marketing Status	TE Code	RLD	RS
ARYMO ER	MORPHINE SULFATE	15MG	TABLET, EXTENDED RELEASE;ORAL	Discontinued	None	Yes	No
ARYMO ER	MORPHINE SULFATE	30MG	TABLET, EXTENDED RELEASE;ORAL	Discontinued	None	Yes	No
ARYMO ER	MORPHINE SULFATE	60MG	TABLET, EXTENDED RELEASE;ORAL	Discontinued	None	Yes	No

Approval Date(s) and History, Letters, Labels, Reviews for NDA 208603

Original Approvals or Tentative Approvals

Action Date	Submission	Action Type	Submission Classification	Review Priority; Orphan Status	Letters, Reviews, Labels, Patient Package Insert	Notes	Url
01/09/2017	ORIG-1	Approval	Type 5 - New Formulation or New Manufacturer	STANDARD	Label (PDF) Letter (PDF) Review		https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/208603s000lbl.pdf https://www.accessdata.fda.gov/drugsatfda_docs/appletter/2017/208603Orig1s000ltr.pdf https://www.accessdata.fda.gov/drugsatfda_docs/nda/2017/208603Orig1s000TOC.cfm

Supplements

Action Date	Submission	Supplement Categories or Approval Type	Letters, Reviews, Labels, Patient Package Insert	Note	Url
10/07/2019	SUPPL-5	Labeling-Medication Guide, Labeling-Package Insert	Label (PDF) Letter (PDF)		https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/208603s005lbl.pdf https://www.accessdata.fda.gov/drugsatfda_docs/appletter/2019/208603Orig1s005ltr.pdf
09/18/2018	SUPPL-4	Labeling-Package Insert	Label (PDF) Letter (PDF)		https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/208603s003s004lbl.pdf https://www.accessdata.fda.gov/drugsatfda_docs/appletter/2018/208603Orig1s003s004ltr.pdf
09/18/2018	SUPPL-3	REMS - MODIFIED - D-N-A	Label (PDF) Letter (PDF)		https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/208603s003s004lbl.pdf https://www.accessdata.fda.gov/drugsatfda_docs/appletter/2018/208603Orig1s003s004ltr.pdf
05/26/2017	SUPPL-2	REMS-Modified	Letter (PDF)	Label is not available on this site.	https://www.accessdata.fda.gov/drugsatfda_docs/appletter/2017/208603Orig1s002ltr.pdf
10/12/2018	SUPPL-1	Efficacy-Labeling Change With Clinical Data	Label (PDF) Letter (PDF)		https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/208603s001lbl.pdf https://www.accessdata.fda.gov/drugsatfda_docs/appletter/2018/208603Orig1s001ltr.pdf

Labels for NDA 208603

Action Date	Submission	Supplement Categories or Approval Type	Letters, Reviews, Labels, Patient Package Insert	Note	Url
10/07/2019	SUPPL-5	Labeling-Medication Guide	Label (PDF)		https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/208603s005lbl.pdf
10/07/2019	SUPPL-5	Labeling-Package Insert	Label (PDF)		https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/208603s005lbl.pdf
10/12/2018	SUPPL-1	Efficacy-Labeling Change With Clinical Data	Label (PDF)		https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/208603s001lbl.pdf
09/18/2018	SUPPL-4	Labeling-Package Insert	Label (PDF)		https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/208603s003s004lbl.pdf
09/18/2018	SUPPL-3	REMS - MODIFIED - D-N-A	Label (PDF)		https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/208603s003s004lbl.pdf
01/09/2017	ORIG-1	Approval	Label (PDF)		https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/208603s000lbl.pdf

Top